Blood-thinning medication linked to slower cognitive decline
People with both atrial fibrillation and Alzheimer's disease who are treated with modern NOAC blood-thinning medicines may experience a slower rate of cognitive decline. This is shown by a study from Karolinska Institutet published in the European Heart Journal.
A recent study published in the European Heart Journal reveals that individuals with both atrial fibrillation and Alzheimer's disease who are treated with modern blood-thinning medications known as NOACs may experience a slower rate of cognitive decline. The research, conducted by Karolinska Institutet, involved analyzing data from 7,308 patients with both conditions.
These participants were divided into three groups: those treated with NOACs, those receiving the older anticoagulant warfarin, and those not using any anticoagulant medication. Over time, the patients treated with NOACs showed a significantly slower decline in cognitive function, with a difference of approximately 0.2 MMSE points per year compared to those on warfarin or no treatment.
While the difference may seem small on an individual basis, it could have a cumulative effect over time. The study also found that patients treated with NOACs had lower risks of death, stroke, blood clots, and fractures compared to those not receiving anticoagulant treatment. However, warfarin was associated with a higher risk of major bleeding.
Although this observational study cannot definitively establish causality, it suggests that NOAC treatment may have positive implications for cognition in patients with atrial fibrillation and Alzheimer's disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
